Global Neurology Academy
The Global Neurology Academy (GNA) series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome.
For more information about GNA, visit www.globalneurologyacademy.org.
136-150 of 249
Symptom Control in gMG: Comparing Ravulizumab and Efgartigimod
NeuroFrontiersSymptom Control in gMG: Comparing Ravulizumab and Efgartigimod
Christopher A. Scheiner, MD, PhD
Exploring Timing in MS Therapy: Real-World Outcomes of Fumarates
NeuroFrontiersExploring Timing in MS Therapy: Real-World Outcomes of Fumarates
Managing MS in Older Adults: Top 5 Clinical Considerations
NeuroFrontiersManaging MS in Older Adults: Top 5 Clinical Considerations
Yinan Zhang, MD
Empowering Patients with CIDP: Education, Support, and Personalized Care Strategies
On the Frontlines of CIDPEmpowering Patients with CIDP: Education, Support, and Personalized Care Strategies
Danielle Minetti
Ryan Quigley
New Frontiers in CIDP Care: Exploring Approved and Emerging Therapies
On the Frontlines of CIDPNew Frontiers in CIDP Care: Exploring Approved and Emerging Therapies
Chafic Karam, MD
Ryan Quigley
Updates from MINT: Inebilizumab Reduces Relapses and Rescue Therapy Use
NeuroFrontiersUpdates from MINT: Inebilizumab Reduces Relapses and Rescue Therapy Use
Richard Nowak, MD, MS
- advertisement
Innovations in Bladder Monitoring for MS: Advancing Remote Evaluation Tools
NeuroFrontiersInnovations in Bladder Monitoring for MS: Advancing Remote Evaluation Tools
Riley Bove, MD, MMSc
How Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
NeuroFrontiersHow Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
John A. Morren, MD, FAAN, FAANEM
Managing MS in Women: How to Guide Patients Through Pregnancy and Menopause
NeuroFrontiersManaging MS in Women: How to Guide Patients Through Pregnancy and Menopause
Riley Bove, MD, MMSc
Anti-Fibrotic ADCs Show Promise in Muscle Preservation for DMD
NeuroFrontiersAnti-Fibrotic ADCs Show Promise in Muscle Preservation for DMD
Emerging Biomarkers for Remyelination in MS: From Fluid Markers to Imaging
NeuroFrontiersEmerging Biomarkers for Remyelination in MS: From Fluid Markers to Imaging
Ahmed Abdelhak, MD
Collaborative MS Care: Strategies for Empowering Patients and Supporting Brain Health
NeuroFrontiersCollaborative MS Care: Strategies for Empowering Patients and Supporting Brain Health
Mary Rensel, MD, FAAN, ABIHM
- advertisement
Evaluating Brogidirsen for Exon 44 Skipping in DMD: Early-Phase Insights
NeuroFrontiersEvaluating Brogidirsen for Exon 44 Skipping in DMD: Early-Phase Insights
Quality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
NeuroFrontiersQuality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
Maxwell H. Levy, MD
Debunking gMG Myths: Counseling Strategies That Change the Conversation
NeuroFrontiersDebunking gMG Myths: Counseling Strategies That Change the Conversation
Maxwell H. Levy, MD
